Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment

Huizhong Xiong(Translational Research in Oncology), Rafael Cubas(Theravance Biopharma (United States)), Ryan Rodriguez(Translational Research in Oncology), Stephanie Mittman(Translational Research in Oncology), Yagai Yang, Dorothee Nickles, Марина Москаленко(Translational Research in Oncology), Patricia Pacheco-Sanchez(Translational Research in Oncology)
Cancer Research
January 24, 2019
10.1158/0008-5472.can-18-3208
Cited by 202

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
|Cancer Cell|2014|1.1k
Inadequate T follicular cell help impairs B cell immunity during HIV infection
|Nature Medicine|2013|362
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
|Immunity|2022|362
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
|Nature|2024|134